13.31
price down icon0.22%   -0.03
after-market アフターアワーズ: 13.31
loading
前日終値:
$13.34
開ける:
$13.4
24時間の取引高:
353.02K
Relative Volume:
0.45
時価総額:
$867.48M
収益:
-
当期純損益:
$-119.67M
株価収益率:
-4.8755
EPS:
-2.73
ネットキャッシュフロー:
$-97.30M
1週間 パフォーマンス:
-7.05%
1か月 パフォーマンス:
-3.34%
6か月 パフォーマンス:
+29.73%
1年 パフォーマンス:
-0.82%
1日の値動き範囲:
Value
$13.28
$13.50
1週間の範囲:
Value
$13.28
$14.74
52週間の値動き範囲:
Value
$8.241
$18.38

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name
名前
Mineralys Therapeutics Inc
Name
セクター
Healthcare (1163)
Name
電話
(888) 378-6240
Name
住所
150 N. RADNOR CHESTER ROAD, RADNOR
Name
職員
51
Name
Twitter
Name
次回の収益日
2024-11-12
Name
最新のSEC提出書
Name
MLYS's Discussions on Twitter

MLYS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MLYS
Mineralys Therapeutics Inc
13.31 869.44M 0 -119.67M -97.30M -2.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-11 開始されました Jefferies Hold
2024-07-10 開始されました H.C. Wainwright Buy
2024-04-02 開始されました Goldman Buy
2023-03-07 開始されました BofA Securities Buy
2023-03-07 開始されました Credit Suisse Outperform
2023-03-07 開始されました Evercore ISI Outperform
2023-03-07 開始されました Guggenheim Buy
2023-03-07 開始されました Stifel Buy
2023-03-07 開始されました Wells Fargo Overweight
すべてを表示

Mineralys Therapeutics Inc (MLYS) 最新ニュース

pulisher
06:08 AM

What drives Mineralys Therapeutics Inc. stock priceTriple-digit return opportunities - Autocar Professional

06:08 AM
pulisher
04:47 AM

What analysts say about Mineralys Therapeutics Inc. stockRecord-breaking gains - Autocar Professional

04:47 AM
pulisher
Jul 22, 2025

Mineralys Therapeutics Inc. Stock Analysis and ForecastMarket-crushing profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

Is Mineralys Therapeutics Inc. a good long term investmentFree Stock Selection - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 17, 2025

Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD - MSN

Jul 17, 2025
pulisher
Jul 17, 2025

(MLYS) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jul 17, 2025
pulisher
Jul 15, 2025

Mineralys Therapeutics CFO Adam Levy sells $155k in stock By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

Mineralys Therapeutics CEO Congleton sells $230k in shares By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

MLYS SEC FilingsMineralys Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 15, 2025
pulisher
Jul 15, 2025

Mineralys Therapeutics, Inc. (MLYS) Receives a Hold from Jefferies - The Globe and Mail

Jul 15, 2025
pulisher
Jul 14, 2025

Jefferies Initiates Mineralys Therapeutics(MLYS.US) With Hold Rating, Announces Target Price $15 - 富途牛牛

Jul 14, 2025
pulisher
Jul 14, 2025

Promising Investment Opportunity in Mineralys Therapeutics Driven by Lorundrostat’s Clinical Success - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Jefferies maintains Hold rating on Mineralys stock amid AstraZeneca data By Investing.com - Investing.com South Africa

Jul 14, 2025
pulisher
Jul 14, 2025

Jefferies maintains Hold rating on Mineralys stock amid AstraZeneca data - Investing.com Australia

Jul 14, 2025
pulisher
Jul 14, 2025

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat - insights.citeline.com

Jul 14, 2025
pulisher
Jul 03, 2025

Mineralys Therapeutics: Navigating Cash Burn and Clinical Triumphs in a $200B Market - AInvest

Jul 03, 2025
pulisher
Jul 03, 2025

Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment - MSN

Jul 03, 2025
pulisher
Jul 02, 2025

Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat - MSN

Jul 02, 2025
pulisher
Jul 02, 2025

Here's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation - Yahoo.co

Jul 02, 2025
pulisher
Jul 02, 2025

Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement - MyChesCo

Jul 02, 2025
pulisher
Jun 30, 2025

Mineralys reports positive phase 3 results for hypertension drug By Investing.com - Investing.com Canada

Jun 30, 2025
pulisher
Jun 30, 2025

Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 2000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Mineralys reports positive phase 3 results for hypertension drug - Investing.com

Jun 30, 2025
pulisher
Jun 26, 2025

(MLYS) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 26, 2025
pulisher
Jun 25, 2025

Is Mineralys Therapeutics, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025
pulisher
Jun 24, 2025

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca - insights.citeline.com

Jun 24, 2025
pulisher
Jun 23, 2025

Lorundrostat Shows Clinically Meaningful Outcomes in Patients With CKD and Hypertension - Pharmacy Times

Jun 23, 2025
pulisher
Jun 18, 2025

Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Mineralys enhances lorundrostat data package ahead of planned NDA - The Pharma Letter

Jun 18, 2025

Mineralys Therapeutics Inc (MLYS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
大文字化:     |  ボリューム (24 時間):